Viswanath, Ambily Nath Indu Pae, Ae Nim 2024-01-20T11:34:38Z 2024-01-20T11:34:38Z 2021-09-04 2013-08-22 0022-2623 https://pubs.kist.re.kr/handle/201004/127761 Talapatra et al. elucidated the molecular basis of resistance by characterizing the binding interactions between Eg5 and the allosteric inhibitor SB743921. The investigation, employing biochemical, biophysical, and structural analyses, made path-breaking revelations in Eg5 studies and discussed a novel phenomenon "resistance by allostery", which could have far-reaching consequences from a rational drug design perspective. English AMER CHEMICAL SOC PHASE-II INHIBITOR PHARMACOKINETICS CARCINOMA ISPINESIB SB-715992 RECURRENT EG5 Resistance by Allostery: A Novel Perspective for Eg5-Targeted Drug Design Article 10.1021/jm401071u 1 JOURNAL OF MEDICINAL CHEMISTRY, v.56, no.16, pp.6314 - 6316 JOURNAL OF MEDICINAL CHEMISTRY 56 16 6314 6316 scie scopus 000323593400003 2-s2.0-84883163795 Chemistry, Medicinal Pharmacology & Pharmacy Article PHASE-II INHIBITOR PHARMACOKINETICS CARCINOMA ISPINESIB SB-715992 RECURRENT EG5 Eg5 Kinesin Spindle Protein Allostery anticancer